Spiegel Discusses the Phase 2 Study Evaluating CRG-022 in R/R LBCL

Opinion
Video

Jay Spiegel, MD, discusses what led to the initiation of a phase 2 study evaluating CRG-022 in patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.

Jay Spiegel, MD, assistant professor at the University of Miami Health System, discusses what led to the initiation of a phase 2 study (NCT05972720) evaluating CRG-022 (firicabtagene autoleucel; firi-cel), a CD22-directed autologous chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed/refractory large B-cell lymphoma following treatment with CD19-directed CAR T-cell therapy.

The prospective, open-label, multicenter trial is assessing the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022 in this patient population.

Transcription:

0:09 | This is a single-arm, phase 2 study for the purposes of registration testing firi-cel or CRG-022, which is a CD22-targeting CAR in relapsed/refractory diffuse large B-cell lymphoma. The primary end point is overall response rate and the secondary end points are progression-free and overall survival.

0:36 | So far, we are just talking about a trial that is in progress. Phase 2 is supposed to enroll 100 patients total, and about 20 patients have been enrolled to date. This is based on a phase 1 single institution study that I was a part of as a fellow at Stanford, where we tested the same CAR in patients with relapsed diffuse large B-cell lymphoma. Thirty-eight patients were treated.

1:09 | When you think about the kind of classic CAR T [adverse] effects, there was CRS, which was relatively common, but low grade, and neurotoxicity [which was] pretty uncommon, at least relative to axi-cel, severe neurotoxin with less than 5%, and this was typically managed with steroids or tocilizumab. The 1, I would say, relatively unique toxicity with this CAR that is different from other CARs is the incidence of [immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)], which occurred at the higher dose level that we tested in about 1/3 of patients. That actually led us to reduce the dose to 1 million CARs per kg, which is the dose that was taken forward to phase 2. And in those patients, that happened about 10% of the time. That is something that in some cases required prolonged steroids and some other additional agents. The phase 1 study just was accepted for publication in the Lancet, so should be coming out pretty soon.



Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Guillermo Garcia-Manero, MD, an expert on MDS
Related Content